JNJ Stock Price Today (July 2026) — Johnson & Johnson Analysis & Key Metrics 2026-07-17
Johnson & Johnson (JNJ) is trading at $253.04, up 1.23% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $257.50 (1.8% upside).
- Volatility remains elevated (24.96% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.90% YoY) alongside significant competitive pressures.
JNJ Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Johnson & Johnson - Historical Price & Volume
Market Cap
Enterprise Value: $644.30B
P/E Ratio
Forward P/E: 19.96
Revenue Growth
Year over Year
Analyst Target
+1.8% upside potential
Key Investor Questions About JNJ
What investors need to know before buying
Based on current market data, JNJ presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 51.25)
- Fundamentals say: Caution warranted (high leverage concerns)
JNJ's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for JNJ investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $54.99B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, JNJ stock traded between $152.81 and $259.88—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 24.96% annualized volatility and β=0.02, the stock exhibits low sensitivity to market moves—making JNJ suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
The Portfolio That Gives You a $2,000 Raise Every Year
Most investors chase the biggest yield they can find, but the portfolio that actually grows your income year after year is built on a completely different logic. Here is how dividend math quietly delivers something that usually requires a performance review.
The Portfolio That Lets You Cruise Through the News, Unbothered
Every new tariff headline, rate decision, and earnings miss seems to demand a financial response, and that constant pressure is exhausting. There is a way to build a portfolio so sturdy that the daily news cycle loses its grip on your nerves.
3 Dividend Stocks That Have Survived Every Market Crash in July
July has a long history of punishing investors who mistake a good run for a durable business. Three Dividend Kings have kept raising their payouts through every major crash since 1987, and all three just delivered beat-and-raise quarters heading into a summer that already feels shaky.
Here’s the Funding It Takes to Keep Learning Forever
Lifelong learning sounds like a noble habit until you price it out across decades and realize it behaves more like a recurring expense than a one-time splurge. The portfolio that funds it may look nothing like the obvious choice.
If Volatility Stays Low, Here’s What Happens to DIVO’s Monthly Income
DIVO's covered-call strategy looks solid on paper, but two macro forces are quietly working against its monthly payouts in ways most income investors overlook. Here is what the options chain and the Treasury market are signaling right now.
Abbott Just Showed Its Growth Engine Has More Than One Cylinder
The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.
The Real Question Buried Inside Merck Stock's Premium Price
The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.
Jim Cramer Says the Market Is “Dead Wrong” About These 5 Oversold Stocks
Jim Cramer named five blue-chip stocks the market punished after strong earnings, and he's betting that millions of investors and billions of dollars got it completely wrong.
Jim Cramer Says Oracle Is “Going Down” and Avoid Every Liquor Stock. Here’s What He’d Buy Instead
Cramer named specific sectors he's betting on for late 2026 while calling out two popular investments as traps that investors should exit now, regardless of where they bought in.
Why This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 Years
Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.
Frequently Asked Questions
Common investor questions about Johnson & Johnson
Johnson & Johnson (JNJ) is currently trading at $253.04. The RSI (14-day) is at 51.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $257.50 implies 1.8% upside from current levels. Volatility is moderate at 25.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Johnson & Johnson (JNJ): The trailing P/E ratio is 29.32, which is in line with broader market averages. The forward P/E is 19.96, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 4.88, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 7.50. Price-to-Sales is 6.32. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering JNJ, the consensus price target is $257.50. This represents a 1.8% upside from the current price of $253.04. The range spans from a low target of $190.00 to a high target of $285.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Johnson & Johnson (JNJ) pays a dividend with a current yield of approximately 2.12%. The annualized dividend rate is $5.20 per share. The payout ratio is 60.3%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-05-26T00:00:00.000Z.
Key risks for Johnson & Johnson (JNJ) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Johnson & Johnson's (JNJ) current debt and financial health profile: Total debt stands at $54.99B. The debt-to-equity ratio is 67.73, which is moderate and generally manageable for most companies. The current ratio is 1.02, indicating adequate short-term liquidity. The quick ratio is 0.69. The company holds $22.05B in cash and equivalents. Free cash flow is positive at $12.51B, providing a cushion for debt servicing and shareholder returns.